Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, Ingenuity Ink Co-promotion Deal

NEW YORK (GenomeWeb News) – Ingenuity Systems and Affymetrix today announced a deal to co-promote each other's products.

Specifically, the terms of the deal call for the firms to co-promote Ingenuity iReport with Affy's expression microarray products. The combined products, Ingenuity and Affy said, will provide researchers a sample-to-insight continuous workflow "for rapid, confident interpretation of results without the need for bioinformatics experience or support."

Ingenuity iReport is an interactive, web-based report that uses the Ingenuity Knowledge Base of biological and chemical data culled from peer-reviewed literature and databases.

"Bundling together our robust expression microarrays with the iReport platform will provide Affymetrix's customers with a simple and accurate tool to convert data into biologically relevant results," Kevin Cannon, senior vice president of the expression business unit at Affy, said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.